Brendan C. Lanpher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brendan C. Lanpher has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Eric W. Klee
Center for Individualized Medicine Mayo Clinic Rochester Minnesota USA
5 shared publications Eric W. Klee
Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
4 shared publicationsErin Conboy
Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA; Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications- Filippo Pinto e Vairo
Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications Linda Hasadsri
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
2 shared publicationsMargot A. Cousin
Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
2 shared publications
Latest Publications
- 13 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Clinical, Genetic, and Endocrine Features of Bardet‐Biedl Syndrome in a Pediatric and Adult Cohort
Bardet‐Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by clinical and genetic heterogeneity. Data on the prevalence of clinical manifestations and comorbidities in BBS, particularly in pediatric patients, are limited. This study aimed to assess the prevalence and various manifestations of endocrine and other clinical comorbidities among pediatric and adult patients with BBS. This retrospective chart review included pediatric and adult patients with BBS evaluated at an academic tertiary care center in the United States between 2000 and 2024. The study included 31 patients (7 children and 24 adults) with seven identified pathogenic variants associated with BBS. The most common genetic etiology was biallelic variants in BBS1 (36%). Obesity was diagnosed in 86% of children and 100% of adults. No children had diabetes or prediabetes, whereas 46% of adults were affected. Dyslipidemia was identified in 29% of children and 46% of adults. No thyroid abnormalities were identified in children, whereas 25% of adults were affected. Retinal dystrophy was present in 71% of children and 96% of adults. Polydactyly was observed in 100% of children and 75% of adults. Chronic kidney disease was present in 29% of children and 63% of adults. This study highlights the clinical heterogeneity and substantial multisystem burden of BBS across pediatric and adult patients. The greater prevalence of diabetes/prediabetes, dyslipidemia, thyroid abnormalities, chronic kidney disease, and visual impairment among adults suggests that these complications may emerge or progress over time. Early recognition, proactive longitudinal surveillance, and comprehensive multidisciplinary care are essential to optimize management across the lifespan.
- 13 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Clinical, Genetic, and Endocrine Features of Bardet‐Biedl Syndrome in a Pediatric and Adult Cohort
Bardet‐Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by clinical and genetic heterogeneity. Data on the prevalence of clinical manifestations and comorbidities in BBS, particularly in pediatric patients, are limited. This study aimed to assess the prevalence and various manifestations of endocrine and other clinical comorbidities among pediatric and adult patients with BBS. This retrospective chart review included pediatric and adult patients with BBS evaluated at an academic tertiary care center in the United States between 2000 and 2024. The study included 31 patients (7 children and 24 adults) with seven identified pathogenic variants associated with BBS. The most common genetic etiology was biallelic variants in BBS1 (36%). Obesity was diagnosed in 86% of children and 100% of adults. No children had diabetes or prediabetes, whereas 46% of adults were affected. Dyslipidemia was identified in 29% of children and 46% of adults. No thyroid abnormalities were identified in children, whereas 25% of adults were affected. Retinal dystrophy was present in 71% of children and 96% of adults. Polydactyly was observed in 100% of children and 75% of adults. Chronic kidney disease was present in 29% of children and 63% of adults. This study highlights the clinical heterogeneity and substantial multisystem burden of BBS across pediatric and adult patients. The greater prevalence of diabetes/prediabetes, dyslipidemia, thyroid abnormalities, chronic kidney disease, and visual impairment among adults suggests that these complications may emerge or progress over time. Early recognition, proactive longitudinal surveillance, and comprehensive multidisciplinary care are essential to optimize management across the lifespan.
- 7 November 2024
- Published by Springer Nature in Chromosome Research
- Vol. 32 (4) , 1-7
A familial chromosome 4p16.3 terminal microdeletion that does not cause Wolf-Hirschhorn (4p-) syndrome
- 7 November 2024
- Published by Springer Nature in Chromosome Research
- Vol. 32 (4) , 1-7
A familial chromosome 4p16.3 terminal microdeletion that does not cause Wolf-Hirschhorn (4p-) syndrome
- 5 December 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 12, 2754-2760
Enhancing Patient Care in Rare Genetic Diseases: An HPO-based Phenotyping Pipeline
Identifying rare genetic diseases poses challenges, often resulting in delayed referrals to genetic specialty care. Consequently, a large number of rare diseases remain undiagnosed for years, with many of these patients often dying without an accurate diagnosis. To help address these diagnostic odysseys, we propose a two-step pipeline using natural language processing (NLP) and machine learning (ML) techniques leveraging raw clinical text narratives of patients from longitudinal clinical data in electronic health records (EHR). Our approach employs two state-of-the-art concept recognition algorithms, ClinPhen and PhenoTagger, to extract human phenotype ontology (HPO) terms from the clinical notes and ML algorithms to identify patients who may benefit from referral. By identifying key phrases indicative of rare diseases, our system can prompt healthcare providers to seek clinical genomics consultations, improving diagnosis and patient outcomes. We evaluated the predictive performance of extracted HPO terms using different ML models. Our strategy and methodological approach are intended to serve as complementary steps in aiding clinicians and researchers to improve the diagnosis efficiency of rare genetic diseases.
- 5 December 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 12, 2754-2760
Enhancing Patient Care in Rare Genetic Diseases: An HPO-based Phenotyping Pipeline
Identifying rare genetic diseases poses challenges, often resulting in delayed referrals to genetic specialty care. Consequently, a large number of rare diseases remain undiagnosed for years, with many of these patients often dying without an accurate diagnosis. To help address these diagnostic odysseys, we propose a two-step pipeline using natural language processing (NLP) and machine learning (ML) techniques leveraging raw clinical text narratives of patients from longitudinal clinical data in electronic health records (EHR). Our approach employs two state-of-the-art concept recognition algorithms, ClinPhen and PhenoTagger, to extract human phenotype ontology (HPO) terms from the clinical notes and ML algorithms to identify patients who may benefit from referral. By identifying key phrases indicative of rare diseases, our system can prompt healthcare providers to seek clinical genomics consultations, improving diagnosis and patient outcomes. We evaluated the predictive performance of extracted HPO terms using different ML models. Our strategy and methodological approach are intended to serve as complementary steps in aiding clinicians and researchers to improve the diagnosis efficiency of rare genetic diseases.
- Open Access
- 14 July 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (7) , 931
Expansion of the Genotypic and Phenotypic Spectrum of WASF1-Related Neurodevelopmental Disorder
In humans, de novo truncating variants in WASF1 (Wiskott–Aldrich syndrome protein family member 1) have been linked to presentations of moderate-to-profound intellectual disability (ID), autistic features, and epilepsy. Apart from one case series, there is limited information on the phenotypic spectrum and genetic landscape of WASF1-related neurodevelopmental disorder (NDD). In this report, we describe detailed clinical characteristics of six individuals with WASF1-related NDD. We demonstrate a broader spectrum of neurodevelopmental impairment including more mildly affected individuals. Further, we report new variant types, including a copy number variant (CNV), resulting in the partial deletion of WASF1 in monozygotic twins, and three missense variants, two of which alter the same residue, p.W161. This report adds further evidence that de novo variants in WASF1 cause an autosomal dominant NDD.
- 14 July 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (7) , 931
Open AccessExpansion of the Genotypic and Phenotypic Spectrum of WASF1-Related Neurodevelopmental Disorder
In humans, de novo truncating variants in WASF1 (Wiskott–Aldrich syndrome protein family member 1) have been linked to presentations of moderate-to-profound intellectual disability (ID), autistic features, and epilepsy. Apart from one case series, there is limited information on the phenotypic spectrum and genetic landscape of WASF1-related neurodevelopmental disorder (NDD). In this report, we describe detailed clinical characteristics of six individuals with WASF1-related NDD. We demonstrate a broader spectrum of neurodevelopmental impairment including more mildly affected individuals. Further, we report new variant types, including a copy number variant (CNV), resulting in the partial deletion of WASF1 in monozygotic twins, and three missense variants, two of which alter the same residue, p.W161. This report adds further evidence that de novo variants in WASF1 cause an autosomal dominant NDD.
- Open Access
- 27 May 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (8) , 2417-2433
TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study
Biallelic loss‐of‐function variants in the thrombospondin‐type laminin G domain and epilepsy‐associated repeats (TSPEAR) gene have recently been associated with ectodermal dysplasia and hearing loss. The first reports describing a TSPEAR disease association identified this gene is a cause of nonsyndromic hearing loss, but subsequent reports involving additional affected families have questioned this evidence and suggested a stronger association with ectodermal dysplasia. To clarify genotype–phenotype associations for TSPEAR variants, we characterized 13 individuals with biallelic TSPEAR variants. Individuals underwent either exome sequencing or panel‐based genetic testing. Nearly all of these newly reported individuals (11/13) have phenotypes that include tooth agenesis or ectodermal dysplasia, while three newly reported individuals have hearing loss. Of the individuals displaying hearing loss, all have additional variants in other hearing‐loss‐associated genes, specifically TMPRSS3, GJB2, and GJB6, that present competing candidates for their hearing loss phenotype. When presented alongside previous reports, the overall evidence supports the association of TSPEAR variants with ectodermal dysplasia and tooth agenesis features but creates significant doubt as to whether TSPEAR variants are a monogenic cause of hearing loss. Further functional evidence is needed to evaluate this phenotypic association.
- 27 May 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (8) , 2417-2433
Open AccessTSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study
Biallelic loss‐of‐function variants in the thrombospondin‐type laminin G domain and epilepsy‐associated repeats (TSPEAR) gene have recently been associated with ectodermal dysplasia and hearing loss. The first reports describing a TSPEAR disease association identified this gene is a cause of nonsyndromic hearing loss, but subsequent reports involving additional affected families have questioned this evidence and suggested a stronger association with ectodermal dysplasia. To clarify genotype–phenotype associations for TSPEAR variants, we characterized 13 individuals with biallelic TSPEAR variants. Individuals underwent either exome sequencing or panel‐based genetic testing. Nearly all of these newly reported individuals (11/13) have phenotypes that include tooth agenesis or ectodermal dysplasia, while three newly reported individuals have hearing loss. Of the individuals displaying hearing loss, all have additional variants in other hearing‐loss‐associated genes, specifically TMPRSS3, GJB2, and GJB6, that present competing candidates for their hearing loss phenotype. When presented alongside previous reports, the overall evidence supports the association of TSPEAR variants with ectodermal dysplasia and tooth agenesis features but creates significant doubt as to whether TSPEAR variants are a monogenic cause of hearing loss. Further functional evidence is needed to evaluate this phenotypic association.
- Open Access
- 20 November 2020
- Published by Wiley in JIMD Reports
- Vol. 58 (1) , 21-28
Bilateral subdural hematomas and retinal hemorrhages mimicking nonaccidental trauma in a patient with D‐2‐hydroxyglutaric aciduria
- 20 November 2020
- Published by Wiley in JIMD Reports
- Vol. 58 (1) , 21-28
Open AccessBilateral subdural hematomas and retinal hemorrhages mimicking nonaccidental trauma in a patient with D‐2‐hydroxyglutaric aciduria
- Open Access
- 10 November 2020
- Published by Springer Nature in BMC Medical Genetics
- Vol. 21 (1) , 1-6
Novel loss-of-function variants in TRIO are associated with neurodevelopmental disorder: case report
Background: Damaging variants inTRIOhave been associated with moderate to severe neurodevelopmental disorders in humans. While recent work has delineated the positional effect of missense variation on the resulting phenotype, the clinical spectrum associated with loss-of-function variation has yet to be fully defined.Case presentation: We report on two probands with novel loss-of-function variants inTRIO. Patient 1 presents with a severe neurodevelopmental disorder and macrocephaly. TheTRIOvariant is inherited from his affected mother. Patient 2 presents with moderate developmental delays, microcephaly, and cutis aplasia with a frameshift variant of unknown inheritance.Conclusions: We describe two patients with neurodevelopmental disorder, macro/microcephaly, and cutis aplasia in one patient. Both patients have loss-of-function variants, helping to further characterize how these types of variants affect the phenotypic spectrum associated withTRIO. We also present the third reported case of autosomal dominant inheritance of a damaging variant inTRIO.
- 10 November 2020
- Published by Springer Nature in BMC Medical Genetics
- Vol. 21 (1) , 1-6
Open AccessNovel loss-of-function variants in TRIO are associated with neurodevelopmental disorder: case report
Background: Damaging variants inTRIOhave been associated with moderate to severe neurodevelopmental disorders in humans. While recent work has delineated the positional effect of missense variation on the resulting phenotype, the clinical spectrum associated with loss-of-function variation has yet to be fully defined.Case presentation: We report on two probands with novel loss-of-function variants inTRIO. Patient 1 presents with a severe neurodevelopmental disorder and macrocephaly. TheTRIOvariant is inherited from his affected mother. Patient 2 presents with moderate developmental delays, microcephaly, and cutis aplasia with a frameshift variant of unknown inheritance.Conclusions: We describe two patients with neurodevelopmental disorder, macro/microcephaly, and cutis aplasia in one patient. Both patients have loss-of-function variants, helping to further characterize how these types of variants affect the phenotypic spectrum associated withTRIO. We also present the third reported case of autosomal dominant inheritance of a damaging variant inTRIO.
- Open Access
Pathogenic SPTBN1 variants cause a novel autosomal dominant neurodevelopmental syndrome
SPTBN1 encodes βII-spectrin, the ubiquitously expressed member of the β-spectrin family that forms micrometer-scale networks associated with plasma membranes. βII-spectrin is abundantly expressed in the brain, where it is essential for neuronal development and connectivity. Mice deficient in neuronal βII-spectrin expression have defects in cortical organization, global developmental delay, dysmorphisms, and behavioral deficiencies of corresponding severity. These phenotypes, while less severe, are observed in haploinsufficient animals, suggesting that individuals carrying heterozygous variants in this gene may also present with measurable compromise of neural development and function. Here we report the identification of heterozygous SPTBN1 variants in 29 individuals who present with global developmental, language and motor delays, mild to severe intellectual disability, autistic features, seizures, behavioral and movement abnormalities, hypotonia, and variable dysmorphic facial features. We show that these SPTBN1 variants lead to loss-of-function, gain-of-function, and dominant negative effects that affect protein stability, disrupt binding to key protein partners, and disturb cytoskeleton organization and dynamics. Our studies define the genetic basis of this new neurodevelopmental syndrome, expand the set of spectrinopathies affecting the brain and neural development, and underscore the critical role of βII-spectrin in the central nervous system.
Open AccessPathogenic SPTBN1 variants cause a novel autosomal dominant neurodevelopmental syndrome
SPTBN1 encodes βII-spectrin, the ubiquitously expressed member of the β-spectrin family that forms micrometer-scale networks associated with plasma membranes. βII-spectrin is abundantly expressed in the brain, where it is essential for neuronal development and connectivity. Mice deficient in neuronal βII-spectrin expression have defects in cortical organization, global developmental delay, dysmorphisms, and behavioral deficiencies of corresponding severity. These phenotypes, while less severe, are observed in haploinsufficient animals, suggesting that individuals carrying heterozygous variants in this gene may also present with measurable compromise of neural development and function. Here we report the identification of heterozygous SPTBN1 variants in 29 individuals who present with global developmental, language and motor delays, mild to severe intellectual disability, autistic features, seizures, behavioral and movement abnormalities, hypotonia, and variable dysmorphic facial features. We show that these SPTBN1 variants lead to loss-of-function, gain-of-function, and dominant negative effects that affect protein stability, disrupt binding to key protein partners, and disturb cytoskeleton organization and dynamics. Our studies define the genetic basis of this new neurodevelopmental syndrome, expand the set of spectrinopathies affecting the brain and neural development, and underscore the critical role of βII-spectrin in the central nervous system.
- Open Access
- 9 June 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (6) , 1013-1028
Expanding the clinical and phenotypic heterogeneity associated with biallelic variants in ACO2
Objective: We describe the clinical characteristics and genetic etiology of several new cases within the ACO2‐related disease spectrum. Mitochondrial aconitase (ACO2) is a nuclear‐encoded tricarboxylic acid cycle enzyme. Homozygous pathogenic missense variants in the ACO2 gene were initially associated with infantile degeneration of the cerebrum, cerebellum, and retina, resulting in profound intellectual and developmental disability and early death. Subsequent studies have identified a range of homozygous and compound heterozygous pathogenic missense, nonsense, frameshift, and splice‐site ACO2 variants in patients with a spectrum of clinical manifestations and disease severities.Methods: We describe a cohort of five novel patients with biallelic pathogenic variants in ACO2. We review the clinical histories of these patients as well as the molecular and functional characterization of the associated ACO2 variants and compare with those described previously in the literature.Results: Two siblings with relatively mild symptoms presented with episodic ataxia, mild developmental delays, severe dysarthria, and behavioral abnormalities including hyperactivity and depressive symptoms with generalized anxiety. One patient presented with the classic form with cerebellar hypoplasia, ataxia, seizures, optic atrophy, and retinitis pigmentosa. Another unrelated patient presented with ataxia but developed severe progressive spastic quadriplegia. Another patient demonstrated a spinal muscular atrophy‐like presentation with severe neonatal hypotonia, diminished reflexes, and poor respiratory drive, leading to ventilator dependence until death at the age of 9 months.Interpretation: In this study, we highlight the importance of recognizing milder forms of the disorder, which may escape detection due to atypical disease presentation.
- 9 June 2020
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (6) , 1013-1028
Open AccessExpanding the clinical and phenotypic heterogeneity associated with biallelic variants in ACO2
Objective: We describe the clinical characteristics and genetic etiology of several new cases within the ACO2‐related disease spectrum. Mitochondrial aconitase (ACO2) is a nuclear‐encoded tricarboxylic acid cycle enzyme. Homozygous pathogenic missense variants in the ACO2 gene were initially associated with infantile degeneration of the cerebrum, cerebellum, and retina, resulting in profound intellectual and developmental disability and early death. Subsequent studies have identified a range of homozygous and compound heterozygous pathogenic missense, nonsense, frameshift, and splice‐site ACO2 variants in patients with a spectrum of clinical manifestations and disease severities.Methods: We describe a cohort of five novel patients with biallelic pathogenic variants in ACO2. We review the clinical histories of these patients as well as the molecular and functional characterization of the associated ACO2 variants and compare with those described previously in the literature.Results: Two siblings with relatively mild symptoms presented with episodic ataxia, mild developmental delays, severe dysarthria, and behavioral abnormalities including hyperactivity and depressive symptoms with generalized anxiety. One patient presented with the classic form with cerebellar hypoplasia, ataxia, seizures, optic atrophy, and retinitis pigmentosa. Another unrelated patient presented with ataxia but developed severe progressive spastic quadriplegia. Another patient demonstrated a spinal muscular atrophy‐like presentation with severe neonatal hypotonia, diminished reflexes, and poor respiratory drive, leading to ventilator dependence until death at the age of 9 months.Interpretation: In this study, we highlight the importance of recognizing milder forms of the disorder, which may escape detection due to atypical disease presentation.
- 1 July 2019
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 105 (1) , 108-121
RINT1 Bi-allelic Variations Cause Infantile-Onset Recurrent Acute Liver Failure and Skeletal Abnormalities
- 1 July 2019
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 105 (1) , 108-121
RINT1 Bi-allelic Variations Cause Infantile-Onset Recurrent Acute Liver Failure and Skeletal Abnormalities